Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Mol Med Rep ; 10(1): 405-10, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-24756411

RESUMO

Naphthoquinones interact with biological systems by generating reactive oxygen species (ROS) that can damage cancer cells. The cytotoxicity and the antitumor activity of 3­acyl­2­phenylamino­1,4­naphthoquinones (DPB1­DPB9) were evaluated in the MCF7 human breast cancer cell line and in male Ehrlich tumor­bearing Balb/c mice. DPB4 was the most cytotoxic derivative against MCF7 cells (EC50 15 µM) and DPB6 was the least cytotoxic one (EC50 56 µM). The 1,4­naphthoquinone derivatives were able to cause DNA damage and promote DNA fragmentation as shown by the plasmid DNA cleavage assay (FII form). In addition, 1,4­naphthoquinone derivatives possibly interacted with DNA as intercalating agents, which was demonstrated by the changes caused in the fluorescence of the DNA­ethidium bromide complexes. Cell death of MCF7 cells induced by 3­acyl­2­phenylamino­1,4­naphthoquinones was mostly due to apoptosis. The DNA fragmentation and subsequent apoptosis may be correlated to the redox potential of the 1,4­naphthoquinone derivatives that, once present in the cell nucleus, led to the increased generation of ROS. Finally, certain 1,4­naphthoquinone derivatives and particularly DPB4 significantly inhibited the growth of Ehrlich ascites tumors in mice (73%).


Assuntos
Antineoplásicos/toxicidade , Apoptose/efeitos dos fármacos , DNA/metabolismo , Substâncias Intercalantes/toxicidade , Naftoquinonas/toxicidade , Espécies Reativas de Oxigênio/metabolismo , Animais , Antineoplásicos/química , Carcinoma de Ehrlich/tratamento farmacológico , DNA/química , Dano ao DNA/efeitos dos fármacos , Humanos , Substâncias Intercalantes/química , Substâncias Intercalantes/uso terapêutico , Células MCF-7 , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Naftoquinonas/química , Naftoquinonas/uso terapêutico , Transplante Heterólogo
2.
Biochem Biophys Res Commun ; 430(3): 883-8, 2013 Jan 18.
Artigo em Inglês | MEDLINE | ID: mdl-23261463

RESUMO

Pharmacological doses of ascorbate were evaluated for its ability to potentiate the toxicity of sodium orthovanadate (Na(3)VO(4)) in tumor cells. Cytotoxicity, inhibition of cell proliferation, generation of ROS and DNA fragmentation were assessed in T24 cells. Na(3)VO(4) was cytotoxic against T24 cells (EC(50)=5.8 µM at 24 h), but in the presence of ascorbate (100 µM) the EC(50) fell to 3.3 µM. Na(3)VO(4) plus ascorbate caused a strong inhibition of cell proliferation (up to 20%) and increased the generation of ROS (4-fold). Na(3)VO(4) did not directly cleave plasmid DNA, at this aspect no synergism was found occurring between Na(3)VO(4) and ascorbate once the resulting action of the combination was no greater than that of both substances administered separately. Cells from Ehrlich ascites carcinoma-bearing mice were used to determine the activity of antioxidant enzymes, the extent of the oxidative damage and the type of cell death. Na(3)VO(4) alone, or combined with ascorbate, increased catalase activity, but only Na(3)VO(4) plus ascorbate increased superoxide dismutase activity (up to 4-fold). Oxidative damage on proteins and lipids was higher due to the treatment done with Na(3)VO(4) plus ascorbate (2-3-fold). Ascorbate potentiated apoptosis in tumor cells from mice treated with Na(3)VO(4). The results indicate that pharmacological doses of ascorbate enhance the generation of ROS induced by Na(3)VO(4) in tumor cells causing inhibition of proliferation and apoptosis. Apoptosis induced by orthovanadate and ascorbate is closer related to inhibition on Bcl-xL and activation of Bax. Our data apparently rule out a mechanism of cell demise p53-dependent or related to Cdk2 impairment.


Assuntos
Antineoplásicos/farmacologia , Apoptose/efeitos dos fármacos , Ácido Ascórbico/farmacologia , Proliferação de Células/efeitos dos fármacos , Espécies Reativas de Oxigênio/metabolismo , Vanadatos/farmacologia , Animais , Linhagem Celular Tumoral , DNA/efeitos dos fármacos , Fragmentação do DNA , Sinergismo Farmacológico , Humanos , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Plasmídeos/efeitos dos fármacos , Proteína X Associada a bcl-2/agonistas , Proteína bcl-X/antagonistas & inibidores
3.
Int J Cardiol ; 145(1): 27-33, 2010 Nov 05.
Artigo em Inglês | MEDLINE | ID: mdl-19625091

RESUMO

Chronic chagasic cardiac patients are exposed to oxidative stress that apparently contributes to disease progression. Benznidazole (BZN) is the main drug used for the treatment of chagasic patients and its action involves the generation of reactive species. 41 patients with Chagas' heart disease were selected and biomarkers of oxidative stress were measured before and after 2 months of BZN treatment (5 mg/kg/day) and the subsequent antioxidant supplementation with vitamin E (800 UI/day) and C (500 mg/day) during 6 months. Patients were classified according to the modified Los Andes clinical hemodynamic classification in groups IA, IB, II and III, and the activity of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), glutathione S-transferase (GST) and glutathione reductase (GR), as well as the contents of reduced glutathione (GSH), thiobarbituric acid reactive species (TBARS), protein carbonyl (PC), vitamin E and C and nitric oxide (NO), myeloperoxidase (MPO) and adenosine deaminase (ADA) activities were measured in their blood. Excepting in group III, after BZN treatment SOD, CAT, GPx and GST activities as well as PC levels were enhanced while vitamin E levels were decreased in these groups. After antioxidant supplementation the activities of SOD, GPx and GR were decreased whereas PC, TBARS, NO, and GSH levels were decreased. In conclusion, BZN treatment promoted an oxidative insult in such patients while the antioxidant supplementation was able to attenuate this effect by increasing vitamin E levels, decreasing PC and TBARS levels, inhibiting SOD, GPx and GR activities as well as inflammatory markers, mainly in stages with less cardiac involvement.


Assuntos
Antioxidantes/uso terapêutico , Doença de Chagas/tratamento farmacológico , Doença de Chagas/metabolismo , Nitroimidazóis/efeitos adversos , Estresse Oxidativo/efeitos dos fármacos , Antioxidantes/farmacologia , Ácido Ascórbico/sangue , Ácido Ascórbico/farmacologia , Ácido Ascórbico/uso terapêutico , Doença de Chagas/sangue , Doença Crônica , Humanos , Estresse Oxidativo/fisiologia , Substâncias Reativas com Ácido Tiobarbitúrico/metabolismo , Vitamina E/sangue , Vitamina E/farmacologia , Vitamina E/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...